Fortrea und Omico kooperieren zur Förderung der biomarkergestützten Entwicklung von Krebsmedikamenten

Fortrea, a leading global clinical research organization, has partnered with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven cancer drug development. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve study planning, patient recruitment, and access to biomarker-based clinical trials in Australia, leveraging Omico's database of over 23,000 patients and referrals from 1,600+ Australian physicians.